M. Teomete

Clinical Outcome of Turkish Metastatic Breast Cancer Patients with Currently Available Treatment Modalities - Single Center Experience

BACKGROUND Breast cancer is the most common malignancy and the second leading cause of cancer-related death among women in the developed countries. Despite advances in screening, improved local therapies and adjuvant systemic treatments, median survival of metastatic breast cancer patients (MBC) is in the range of 2-3 years at most. We aimed to investigate whether the prognostic factors and therapeutic responses of our Turkish patients are similar to those in the literature. MATERIALS AND METHODS We reviewed the medical records of MBC patients who had been treated in our institution between 1999-2009 and analyzed their clinicopathological features and survival outcomes retrospectively. RESULTS A hundred and sixty patients were included. Median age was 47 (23-82), median follow up was 24 (2-186) months. At the time of diagnosis 59% of patients were under the age of 50 and 46% were postmenopausal. The majority (37%) had multiple sites of metastases. Forty percent received endocrine therapy and 40% chemotherapy as first line metastatic treatment. Thirty (20%) patients were treated with molecular targeting agents like trastuzumab, lapatinib and sunitinib, frequently combined with a chemotherapy agent. Five-year overall survival (OS) was 32% and median OS was 38 months for the whole group. Five year progression free survival (PFS) was 10% and median PFS was 10 months. Menopausal status, hormone receptor expression and disease free status had a significant impact on overall survival in the multivariate analysis (p 0.018, p 0.018 and p:0.003, respectively). CONCLUSIONS All our patients were treated with the modern oncologic therapies recommended by the international guidelines. From our data, MBC patients live up to 3-4 years, indicating that further improvement beyond that requires development of new treatment modalities. The survival outcomes of our patients were consistent with the data reported in the literature.

Weight gain after adjuvant chemotherapy in early breast cancer patients in Istanbul.

e11099 Background: Weight gain is a known and unwanted complication of chemotherapy (CT). We observed that the female Turkish breast cancer (BC) patients (pts) frequently gain weight with adjuvant ...

Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience

15103 Background: Chemoradiotherapy (CRT) after or before resection of high-risk rectal cancer (RC) improves overall survival (OS) and pelvic control. Thus, CRT is the standard adjuvant treatment in resected stage II/III RC. There are limited studies, if any, analyzing the outcome of RC patients with stage II/III who received adjuvant CRT after curative resection in Turkey. Therefore, we aimed to analyze the treatment outcome, and the prognostic significance of various parameters in these patients. Methods: 144 patients with stage II/III RC treated with adjuvant CRT since 1997 until present were analyzed retrospectively. Patients received 5-fluorouracil (375–425mg/m2/day × 5days) and calcium leucovorin (20mg/m2/day × 5days), q4weeks, two courses before and two courses after radiotherapy (RT). The 5- fluorouracil dose was reduced either to 225mg/m2/day given continuously as protracted short-term infusion during RT, or to 375–400 mg/m2/day on the first and last 4 days of RT. 45–50.4 Gy RT was given to the p...

Benefit from adjuvant anthracyclines according to hormone receptor status

11513 Background: Several trials have consistently reported that there is marked heterogeneity in the magnitude of chemotherapy benefit according to the level of hormone receptor expression. Methods: We reviewed the medical records of early breast cancer patients with known receptor status who had anthracycline based adjuvant (CA, CE, CEF or CAF) CT between 1999–2006 in our institution. We recorded the clinical/pathologic characteristics of ER/PR+/+ and ER/PR−/− tumors (tms), analyzed survival outcome according to receptor status. Results: 258 of 318 tumors were both ER,PR positive. In the receptor positive (RP) subset % 40 patients were postmenopausal, %57 had nod positive disease, % 27 had breast conserving surgery (BCS). Her-2 was 2+/3+ in % 12 tms and %67/20 tms were grade 2/3 respectively. In the receptor negative (RN) subset (n:60) all patients were postmenopausal, %48 had nod positive disease, % 24 had BCS. Her-2 was 2+/3+ in % 24 tumors, %60 were triple negative and %41 /55 pts had grade 2/3 tumor...